폐암 치료제 시장 - 규모, 점유율, 성장 분석 : 치료법별, 암 유형별, 분자 유형별, 유통 경로별, 지역별 산업 예측(2026-2033년)

Global Lung Cancer Therapeutics Market size was valued at USD 36.4 Billion in 2024 and is poised to grow from USD 41.2 Billion in 2025 to USD 111.1 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026-2033).

The lung cancer therapeutics market is seeing notable growth, fueled by advancements in diagnostic techniques, innovative treatments, and rising awareness surrounding lung cancer globally. Enhanced government investments in healthcare infrastructure and quality treatment options are critical drivers of this market's expansion. As individuals increasingly recognize the diverse treatment avenues available, market demand intensifies. Furthermore, factors such as rising disposable income, continuous R&D for new technologies, the adoption of advanced radiation therapy, and economic growth in developing nations bolster market prospects. Key players are focusing on innovation and enhancing their product portfolios to improve patient outcomes. Given its high prevalence and significant mortality rate, lung cancer remains a critical area of focus for continued therapeutic advancements in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Therapeutics Market Segments Analysis

Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User and region. Based on Therapy, the market is segmented into Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Others. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). Based on Type of Molecule, the market is segmented into Small molecules and Biologics. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Drug Class, the market is segmented into Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Therapeutics Market

The rising incidence of lung cancer worldwide significantly influences the global lung cancer therapeutics market. Key contributors to this surge include tobacco use, environmental pollution, and changes in lifestyle, all of which have led to a notable increase in diagnosed cases. This escalation is fostering a heightened demand for effective treatment options and innovative therapies aimed at enhancing patient care. As healthcare systems and researchers strive to address this growing challenge, the need for advanced therapeutic solutions continues to evolve, driving progress within the market dedicated to combating lung cancer.

Restraints in the Global Lung Cancer Therapeutics Market

The Global Lung Cancer Therapeutics market faces significant challenges due to stringent regulatory requirements that govern the approval of new therapies. This rigorous and often lengthy process can delay patient access to innovative treatments, hindering timely intervention in managing the disease. Moreover, such restrictive regulations can deter investment in research and development, limiting the flow of new therapies into the market. As a result, these barriers not only slow down advancements in lung cancer treatment options but also create obstacles for healthcare professionals striving to provide the best care for patients battling this serious illness.

Market Trends of the Global Lung Cancer Therapeutics Market

The global lung cancer therapeutics market is witnessing a significant shift towards personalized medicine, characterized by the integration of genetic profiling and biomarkers in treatment design. This transformative approach enhances the effectiveness of therapies while minimizing adverse effects, thereby addressing the unique characteristics of each patient's cancer. As a result, there is a growing demand for targeted therapies and immunotherapies that are specifically aligned with individualized patient profiles. This trend not only represents a fundamental change in the treatment paradigm but also emphasizes the need for ongoing advancements in research and technology to optimize patient outcomes in lung cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Lung Cancer Therapeutics Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Radiation Therapy
  • External Beam
  • Internal Beam
  • Systemic
• Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
• Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
• Chemotherapy
• Others

Global Lung Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)

Global Lung Cancer Therapeutics Market Size by Type of Molecule & CAGR (2026-2033)

• Market Overview
• Small molecules
• Biologics

Global Lung Cancer Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Lung Cancer Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Alkylating Agents
• Antimetabolites
• EGFR Inhibitors
• Mitotic Inhibitors
• Multikinase Inhibitors
• Others

Global Lung Cancer Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Lung Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • US
  • Canada
• Europe (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations